KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Acquisitions (2016 - 2025)

AbbVie (ABBV) has disclosed Acquisitions for 10 consecutive years, with $204.0 million as the latest value for Q1 2025.

  • Quarterly Acquisitions fell 97.78% to $204.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $204.0 million through Dec 2025, down 98.83% year-over-year, with the annual reading at $204.0 million for FY2025, 98.83% down from the prior year.
  • Acquisitions for Q1 2025 was $204.0 million at AbbVie, down from $8.3 billion in the prior quarter.
  • The five-year high for Acquisitions was $9.2 billion in Q1 2024, with the low at $204.0 million in Q1 2025.
  • Average Acquisitions over 3 years is $4.6 billion, with a median of $4.4 billion recorded in 2021.
  • The sharpest move saw Acquisitions soared 330.33% in 2021, then crashed 97.78% in 2025.
  • Over 3 years, Acquisitions stood at $525.0 million in 2021, then skyrocketed by 1479.81% to $8.3 billion in 2024, then plummeted by 97.54% to $204.0 million in 2025.
  • According to Business Quant data, Acquisitions over the past three periods came in at $204.0 million, $8.3 billion, and $9.2 billion for Q1 2025, Q3 2024, and Q1 2024 respectively.